18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.

UNLABELLED We hypothesized that delineation of gliomas from gray matter with 18F-FDG PET could be improved by extending the interval between 18F-FDG administration and PET data acquisition. The purposes of this study were, first, to analyze standard and delayed 18F-FDG PET images visually and quantitatively to determine whether definition of tumor improved at later imaging times and, second, to investigate the dynamics of model-derived kinetic rate constants, particularly k4. METHODS Nineteen adult patients with supratentorial gliomas were imaged from 0 to 90 min and once or twice later at 180-480 min after injection. In 15 patients, arterial sampling provided the early input function. Venous sampling provided the remaining curve to the end of the imaging sequence. Standardized uptake value (SUV) was calculated as tissue concentration of tracer per injected tracer dose per body weight. Ratios of tumor SUV relative to the SUV of gray matter, brain (including gray and white matter), or white matter were calculated at each imaging time point. Dynamic image data from tumor, gray matter, brain, or white matter were analyzed using a 2-compartment, 4-parameter model applied for the entire duration of imaging, in which delay, K1, distribution volume, k3, and k4 were optimized using a nonlinear optimization method. Parameter estimation for each region included both an early subset of data from a conventional dynamic imaging period (0-60 min) and the full, extended dataset for each region. RESULTS In 12 of the 19 patients, visual analysis showed that the delayed images better distinguished the high uptake in tumors relative to uptake in gray matter. SUV comparisons also showed greater uptake in the tumors than in gray matter, brain, or white matter at the delayed times. The estimated k4 values for tumors were not significantly different from those for gray matter in early imaging analysis but were lower (P < 0.01) using the extended-time data. CONCLUSION The kinetic parameter results confirm the visual and SUV interpretation that tumor enhancement is greater than enhancement of surrounding brain regions at later imaging times, consistent with a greater effect of FDG-6-phosphate degradation on normal brain relative to glioma.

[1]  H. Herzog,et al.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer , 1999, European Journal of Nuclear Medicine.

[2]  Yoshiharu Yonekura,et al.  18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  C. Stearns,et al.  Investigation of the count rate performance of the General Electric Advance positron emission tomograph , 1994, Proceedings of 1994 IEEE Nuclear Science Symposium - NSS'94.

[5]  M. Graham,et al.  High-speed automated discrete blood sampling for positron emission tomography. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[8]  A. Blais,et al.  2-Deoxyglucose transport and metabolism in Caco-2 cells. , 1996, The American journal of physiology.

[9]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[10]  P. Marsden,et al.  A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.

[11]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.

[12]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Thomas K. Lewellen,et al.  Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .

[14]  Hiroshi Fukuda,et al.  Advantage of delayed whole-body FDG-PET imaging for tumour detection , 2001, European Journal of Nuclear Medicine.

[15]  Finbarr O'Sullivan,et al.  Reducing negativity artifacts in emission tomography: post-processing filtered backprojection solutions , 1993, IEEE Trans. Medical Imaging.

[16]  A. Alavi,et al.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck , 1999, European Journal of Nuclear Medicine.

[17]  I. Leav,et al.  The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. , 1996, Nuclear medicine and biology.

[18]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  T. Yen,et al.  Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y Yonekura,et al.  Effects of hyperglycemia on FDG uptake in human brain and glioma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  H. Sipilä,et al.  Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[22]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[24]  N. Alpert,et al.  FDG-PET in oncology: there's more to it than looking at pictures. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Sakahara,et al.  Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.

[26]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[27]  S Minoshima,et al.  An automated method for rotational correction and centering of three-dimensional functional brain images. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  F. O’Sullivan,et al.  Metabolic images from dynamic positron emission tomography studies , 1994, Statistical methods in medical research.